Skip to main content
OpenTrials

Clinical trial condition

Neisseriaceae Infections

Explore clinical trials studying Neisseriaceae Infections. Study availability and eligibility vary by location and protocol.

400 public trials 21 recruiting studies
Refine in advanced search Browse all conditions

Neisseriaceae Infections trial results

Completed

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea

NCT01766206

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Ansan, South Korea
  • GSK Investigational Site Anyang, South Korea
  • GSK Investigational Site Bucheon-si, South Korea
  • GSK Investigational Site Busan, South Korea
View all 54 locations
View Trial Details
Completed

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

NCT02140762

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • Accelovance, Inc Huntsville, Alabama, United States
  • The Children's Clinic of Jonesboro, P.A. Jonesboro, Arkansas, United States
  • Accelovance, Inc Melbourne, Florida, United States
  • Heartland Research Associates LLC Newton, Kansas, United States
View Trial Details
Completed

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

NCT00129129

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Fountain Valley, California, United States
  • GSK Investigational Site Centennial, Colorado, United States
  • GSK Investigational Site Norwich, Connecticut, United States
View all 27 locations
View Trial Details
Completed

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

NCT00289783

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Bryant, Arkansas, United States
View all 93 locations
View Trial Details
Completed

Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

NCT02106390

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Diseases, +8 more
Locations
  • GSK Investigational Site Buenos Aires, Argentina
  • GSK Investigational Site Buenos Aires, Argentina
  • GSK Investigational Site Córdoba, Argentina
  • GSK Investigational Site Mexico City, Mexico
View Trial Details
Completed

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

NCT01165242

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Chandler, Arizona, United States
  • GSK Investigational Site Paramount, California, United States
  • GSK Investigational Site Sacramento, California, United States
  • GSK Investigational Site Sacramento, California, United States
View all 32 locations
View Trial Details

Related conditions